Sun, Dec 28, 2014, 11:15 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

camptownn 2 posts  |  Last Activity: Nov 5, 2014 9:17 AM Member since: Oct 28, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • camptownn camptownn Nov 5, 2014 9:17 AM Flag

    AnGes. In 2005, we granted an exclusive worldwide license to AnGes for use of our core DNA delivery technology in the development
    and commercialization of DNA-based products encoding hepatocyte growth factor, or HGF, for cardiovascular applications. HGF is a human
    protein that promotes angiogenesis. AnGes is developing Collategene , a DNA-based delivery of HGF for indications related to PAD, a severe
    condition caused by blockage of blood vessels feeding the foot and lower leg.
    AnGes has obtained a Special protocol assessment from the FDA for a Phase 3 clinical trial of Collategene for patients with Critical limb
    ischemia, but has not yet commenced the study. In December 2013, the last of the patents we licensed to AnGes expired, and as a result the
    license agreement expired in accordance with its terms.

  • Government records show that the National Institute of Allergy and Infectious Diseases ran Ebola vaccine trials in 2003, 2006 and 2008, but none during President Obama’s two terms — until now.

    Mr. Sullivan thought the 2003 trial in which he took part was a success, and he thinks the government, particularly the current administration, missed an opportunity to develop an Ebola vaccine as the war on terrorism waned.

    By 2006, the NIH revealed that he had been given the vaccine, not the control placebo. A scientific report on the study read: “This Ebola virus DNA vaccine was safe and immunogenic in humans.”

    Years later, Mr. Sullivan feels like he is watching reruns.

    Read more:
    Follow us: @washtimes on Twitter

1.07+0.04(+3.88%)Dec 26 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.